Skip Navigation


NDT Advance Access originally published online on July 4, 2007
Nephrology Dialysis Transplantation 2007 22(12):3573-3579; doi:10.1093/ndt/gfm417
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
22/12/3573    most recent
gfm417v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kessler, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kessler, M.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2007]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org



Predictors of cardiovascular events in patients with end-stage renal disease: an analysis from the Fosinopril in Dialysis study

Michèle Kessler1, Faiez Zannad2, Philippe Lehert3, Jean Pierre Grünfeld4, Christian Thuilliez5, Alain Leizorovicz6, Philippe Lechat7 for the FOSIDIAL Investigators

1Department of Nephrology, University Hospital of Nancy, 2Hypertension and Preventive Cardiology Division, Department of Cardiovascular disease, Centre d’Investigations Cliniques INSERM-CHU, INSERM U684, Nancy, France, 3Faculty of Medicine, Melbourne, Australia and Faculty of Economics, FUCAM, Louvain Academy, Belgium, 4Department of Nephrology, Hôpital Necker, Université Paris V – René Descartes, Paris, 5Department of Clinical Pharmacology and Centre d’Investigations Cliniques INSERM-CHU, University Hospital of Rouen, 6Clinical Pharmacology Unit, EA 3736, Université Claude Bernard Lyon 1, Lyon and 7Pharmacology Department, Pitié-Salpêtrière University Hospital, Assistance-Publique Hôpitaux de Paris, Paris 6 University, Paris, France

Correspondence and offprint requests to: Michèle Kessler, MD, Service de Néphrologie, Hôpitaux de Brabois, CHU de Nancy, 54500 Vandoeuvre les Nancy, France. Email: m.kessler{at}chu-nancy.fr



  Abstract

Background. Cardiovascular events (CVE) are a major cause of morbidity and mortality in end-stage renal disease (ESRD) patients. These patients are often excluded from CV clinical trials, and the prognostic factors associated with CVE in patients with ESRD have not been fully explored. A risk prediction model was created from the FOSIDIAL trial to identify factors predictive of CVE and to evaluate the relative strength of known predictors when considered together in a multivariate model.

Methods. FOSIDIAL was a prospective, randomized, double-blind study with 2-year follow-up and CVE adjudication. The study enrolled 397 patients with ESRD and left ventricular hypertrophy (LVH). CVE included cardiovascular death, non-fatal myocardial infarction, unstable angina, stroke, revascularization, heart failure hospitalization, resuscitated cardiac arrest and confirmed stroke. The model was built using a forward selection of all baseline variables. A structural equation model (SEM) was used to identify factors with an indirect association with CVE.

Results. CV history was the most important prognostic factor, followed by C-reactive protein (CRP), left ventricular mass index, diabetes and age. Smoking, low HDL, female gender and Kt/V were indirectly associated with CVE.

Conclusion. Prior CV disease, elevated CRP, LVH, diabetes or advanced age identifies patients at the highest risk for CVE. These data may be useful to detect high risk patients, to define potential targets for pharmacologic intervention, and to plan future studies in ESRD. Further research is needed to identify effective approaches that reduce the rate of CVE in these patients.

Keywords: cardiovascular disease; end-stage renal disease; morbidity; mortality

Received for publication: 12. 3.07
Accepted in revised form: 4. 6.07


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
pdiHome page
A. Unal, M. Sipahioglu, F. Oguz, M. Kaya, H. Kucuk, B. Tokgoz, H. Buyukoglan, O. Oymak, and C. Utas
PULMONARY HYPERTENSION IN PERITONEAL DIALYSIS PATIENTS: PREVALENCE AND RISK FACTORS
Perit. Dial. Int., March 1, 2009; 29(2): 191 - 198.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.